Intero Biosystems
Developing human intestinal organoids for preclinical drug testing, reducing trial costs and enhancing drug safety.
Website: https://www.interobiosystems.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Company | Intero Biosystems |
| Tagline | Developing human intestinal organoids for preclinical drug testing, reducing trial costs and enhancing drug safety. [Intero Biosystems] |
| Headquarters | Denver, United States [TechCrunch, October 2026] |
| Founded | 2024 [TechCrunch, October 2026] |
| Stage | Pre-Seed [Intero Biosystems, June 2025] |
| Business model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Academic Spinout [TechCrunch, October 2026] |
| Funding label | Pre-seed |
| Total disclosed | ~$2,300,000 [TechCrunch, October 2026] |
Links
Publicly reported
- Website: https://www.interobiosystems.com/
- LinkedIn: https://www.linkedin.com/company/intero-biosystems
Summary and Signal
PUBLIC Intero Biosystems is building human intestinal organoids for preclinical drug testing, and it merits investor attention now because it has moved from academic-origin technology into early commercial use while also winning TechCrunch Startup Battlefield 2026, a combination that usually brings sharper customer and financing scrutiny [TechCrunch, October 2026] [TechCrunch, October 2026]. The company was founded in 2024 as a University of Michigan spinout and is now described as Denver-based, with co-founders Charlie Childs, Madeline Eiken, and Jason Spence tied to organoid research at Michigan [TechCrunch, October 2026] [Intero Biosystems, Unknown] [Center for Entrepreneurship, Unknown].
Its core product, GastroScreen, is a stem-cell-derived intestinal organoid platform designed to let pharmaceutical, biotechnology, food, and chemical companies test compound effects in a model intended to be closer to human biology than standard animal studies or flat cell systems [Intero Biosystems, Unknown] [TechCrunch, October 2026] [The Diligent Observer, August 2025]. The technical edge, as publicly described, is tissue complexity: Intero says the organoids include neurons, blood vessels, muscle, and intestinal lining, while third-party coverage consistently frames the product as an "intestine in a dish" rather than a simpler single-cell assay [Intero Biosystems, Unknown] [SBIR.gov] [Tech Bytes, 2026].
The team reads like an academic spinout rather than a repeat-founder commercial build, which is a strength on scientific credibility and a point to monitor on scaling execution; Jason Spence is identified as a University of Michigan professor and organoid-science researcher, while Eiken and Childs are described in university-linked sources as current or former Ph.D. researchers in the same ecosystem [Center for Entrepreneurship, Unknown] [The Spence Lab @ the university of michigan, April 2025] [Forbes, December 2025]. On capital, Intero announced a $2.0 million pre-seed in June 2025 and TechCrunch later reported a $2.3 million pre-seed total by October 2026; the company also won $100,000 in equity-free funding through Startup Battlefield, while Rice Business Plan Competition proceeds appear material but not cleanly separated between prize and investment across sources [Intero Biosystems, June 2025] [TechCrunch, October 2026] [Santa Clara University Bronco Ventures, October 2026].
The business model is B2B, and the early signal that matters is commercial adoption: TechCrunch reported just under 10 customers and a seven-person team by October 2026, which suggests real market testing but still a very early operating base [TechCrunch, October 2026]. Over the next 12 to 18 months, the central questions are whether Intero can convert scientific novelty into repeatable pharma workflows, expand beyond pilot-style engagements, and show that its organoid platform produces decision-useful data that customers will budget for in routine preclinical programs [TechCrunch, October 2026] [Intero Biosystems, Unknown].
No independent source found -- This section combines independent reporting from TechCrunch, Forbes, and university-linked sources with material product claims that remain company-described or only partially corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Pre-seed, total disclosed approximately $2.3 million |
Company Overview
PUBLIC
Intero Biosystems is still early enough that the cleanest way to read it is through what is already on the record: a 2024 founding date, a Denver headquarters, and a narrow initial claim on preclinical testing rather than a broad platform story [Crunchbase] [Intero Biosystems]. On its website, the company describes itself as building "miniature organs for preclinical testing," with an initial focus on stem-cell-derived human intestinal organoids intended to make drug development more human-relevant [Intero Biosystems]. Crunchbase classifies the company as based in Denver, United States, and dates its founding to 2024 [Crunchbase].
The early milestones are straightforward and, for now, mostly financing-led. In June 2025, Intero announced an oversubscribed $2 million pre-seed round and named a broad investor group that included Kalamazoo Forward Ventures, Evoce Capital, Goose Capital, Dr. Nancy Chang, Canyon Oak Ventures, Bronco Venture Fund, Michigan Rise, Accelerate Blue Fund, Michigan University Innovation Capital Fund, Michigan Biomedical Venture Fund, Ann Arbor SPARK Capital, Houston Angel Network, and nCourage Investment Group [Intero Biosystems, June 2025]. By October 2026, TechCrunch reported the company had raised $2.3 million on a pre-seed basis, but that later total is outside the source set permitted for this section, so the conservative public record here remains the company-announced June 2025 round alongside the 2024 founding record on Crunchbase [Intero Biosystems, June 2025] [Crunchbase].
One source, partially checked -- Founded date and headquarters are corroborated by Crunchbase and the company website, while the funding milestone in this section relies on a company press release.
The Product and the Stack
GastroScreen and the organoid model
MIXED Intero Biosystems is selling a fairly specific preclinical-testing proposition, not a broad platform claim. Public materials describe GastroScreen as a human intestinal organoid product used by pharmaceutical, biotechnology, food, and chemical companies to evaluate how drugs and other compounds affect gut tissue before human trials [TechCrunch, October 2026] [Intero Biosystems] [Tech Bytes, 2026]. The company and third-party coverage consistently describe the organoids as lab-grown gut tissues about 1 millimeter across, positioned as a more human-relevant model than animal studies or flat cell layers for at least some intestinal safety and efficacy questions [TechCrunch, October 2026] [Tech Bytes, 2026] [Trend Hunter].
The underlying technical claim is that these are more complex tissues than a standard epithelial assay. Intero says its intestinal organoid contains neurons, blood vessels, muscle, and the inner lining of the intestine, while conference and grant materials similarly describe functional smooth muscle, perfusable vasculature, and neurons responsive to stimuli or present alongside the epithelial layer [Intero Biosystems] [BIO International Convention 2025] [SBIR.gov]. That matters because the company is asking buyers to believe the model captures multicellular gut behavior that simpler in vitro systems can miss, although the strongest detail on exact functionality still comes from company and affiliated materials rather than independent validation studies [Intero Biosystems] [SBIR.gov].
Use case, workflow, and operating signals
MIXED The commercial use case is framed conservatively in the available evidence. Intero and press coverage say GastroScreen is intended to help customers assess general intestinal cytotoxicity, cell-type-specific toxicity, off-target effects, and epithelial barrier disruption, with the broader aim of reducing reliance on animal models in preclinical work [Intero Biosystems] [TechCrunch, October 2026]. SBIR language is narrower and more useful here: it says the human intestinal organoid system will be validated and optimized for cell viability and cytotoxicity assays, which suggests the current commercial wedge may be safety testing first, with broader efficacy or mechanistic claims still needing more external proof [SBIR.gov].
A few operating details help ground the product beyond website copy. TechCrunch reported in October 2026 that Intero had just under 10 customers, and separate coverage said studies were underway with several pharmaceutical companies, which indicates the product has moved beyond pure lab prototype status into early commercial evaluation [TechCrunch, October 2026]. On manufacturing and delivery, public signals are thin but directionally relevant: one outlet reported that Intero ships roughly 100 organoids in a tube, and the presence of a Principal Scientist, Manufacturing opening points to reproducibility and scale-up as active technical priorities rather than solved problems [Межа] [LinkedIn].
One source, partially checked -- Core product description is corroborated by TechCrunch, the company website, and conference or grant materials, but several capability claims still rely on company-authored or affiliated sources.
The Market They Are Entering
PUBLIC
The market matters now because drug developers are under steady pressure to improve the predictive value of preclinical testing, and Intero is positioning itself at the point where that pressure meets a specific biological bottleneck: intestinal safety and efficacy assessment before human trials [TechCrunch, October 2026] [Intero Biosystems].
The available public record does not provide a named third-party TAM, SAM, or SOM for Intero’s exact segment, which is human intestinal organoids for preclinical testing. That limits precision, and it matters because organoids sit across several adjacent markets rather than inside one clean category. On the evidence available, the closer public framing is an enabling tool for preclinical drug testing and human-relevant alternatives to animal models, with Intero specifically selling GastroScreen to pharmaceutical, biotechnology, food, and chemical companies for compound assessment before human trials [TechCrunch, October 2026] [Intero Biosystems] [The Diligent Observer, August 2025].
Demand drivers are easier to document than market size. Intero’s product claims, and much of the third-party coverage, rest on a familiar pain point in drug development: animal models and simple cell layers can miss human-specific toxicity or tissue-level effects, especially in the gut, where barrier function, smooth muscle, vasculature, and neuronal activity all matter to compound response [Trend Hunter] [BIO International Convention 2025] [SBIR.gov]. That framing is still partly company-led, but it is directionally supported by public coverage describing GastroScreen as a more human-relevant preclinical model and by TechCrunch’s report that studies were underway with several pharmaceutical companies involving both existing compounds and new drug candidates [TechCrunch, October 2026] [Trend Hunter].
The adjacent markets are broader than biopharma alone. Intero’s stated buyer set includes food and chemical companies in addition to pharma and biotech, which suggests the company is aiming at a wider toxicology and compound-screening budget pool rather than a single drug-discovery line item [TechCrunch, October 2026] [Intero Biosystems]. The substitute set is also clear enough from the sources: legacy animal studies, flat cell culture systems, and other in vitro preclinical assays remain the incumbent pathways that any organoid-based workflow has to complement or displace over time [Forbes, December 2025] [Trend Hunter].
Regulatory and macro forces appear supportive in broad terms, though the evidence here is more thematic than quantified. Multiple sources describe the product as reducing reliance on animal testing or offering an alternative to it, which aligns with a wider industry push toward human-relevant systems in preclinical R&D, even if the sources provided do not cite a specific regulatory mandate or reimbursement catalyst for Intero’s category [Forbes, December 2025] [Intero Biosystems] [The Diligent Observer, August 2025]. The practical implication is that adoption will likely hinge less on policy alone and more on whether organoid assays can show repeatability, throughput, and decision usefulness inside existing preclinical workflows.
| Market lens | What public sources support | Source quality |
|---|---|---|
| Core market | Human intestinal organoids for preclinical drug and compound testing | Company and media corroboration [Intero Biosystems] [TechCrunch, October 2026] |
| Adjacent market | Human-relevant in vitro models as alternatives or complements to animal testing | Media and company framing [Forbes, December 2025] [Trend Hunter] [Intero Biosystems] |
| Buyer budget centers | Pharma, biotech, food, and chemical testing budgets | Media and company corroboration [TechCrunch, October 2026] [Intero Biosystems] |
| Main substitutes | Animal models, flat cell layers, conventional preclinical assays | Third-party and company-adjacent descriptions [Forbes, December 2025] [Trend Hunter] [SBIR.gov] |
The table shows a market that is credible in need-state terms but still loosely bounded in sizing terms. For investors, that usually shifts diligence toward workflow fit, assay validation, and budget ownership rather than top-down TAM arithmetic.
One source, partially checked -- Section relies on named public sources for category framing and demand drivers, but no cited third-party market sizing report was available for Intero’s exact segment.
The Competitive Field
MIXED Intero Biosystems is competing less against one clearly disclosed startup set than against the current preclinical workflow itself, which still centers on animal models and simpler in vitro systems as the default comparator [TechCrunch, October 2026] [Intero Biosystems] [Trend Hunter].
The public record is unusually thin on named direct competitors, so the most defensible map is by substitute category rather than by startup roster. At the incumbent end, animal testing remains the reference workflow that Intero is explicitly trying to replace or augment with human-relevant intestinal models [Intero Biosystems] [TechCrunch, October 2026]. Adjacent substitutes include conventional flat cell layers and other lower-complexity lab assays, which outside coverage describes as biologically less representative than Intero's organoid system [Trend Hunter]. A third bucket is internal pharma preclinical infrastructure, where a buyer may compare GastroScreen not only with an external vendor but with in-house assay development and existing CRO relationships, although no specific CRO rivals are named in the cited sources.
Intero's edge today appears to rest on technical specificity and founder-market fit rather than on distribution. The company describes GastroScreen as a stem-cell-derived human intestinal organoid with neurons, blood vessels, muscle, and intestinal lining, and third-party coverage similarly frames the product as a more complete "intestines in a dish" model for assessing compound effects before human trials [Intero Biosystems] [BIO International Convention 2025] [The Diligent Observer, August 2025]. That is a meaningful wedge if customers care about gut-specific toxicity, barrier disruption, or off-target effects that simpler assays may miss [Intero Biosystems]. The durability question is less settled. Scientific know-how tied to Jason Spence's organoid research background and the University of Michigan spinout origin could be a real moat at this stage [Center for Entrepreneurship] [TechCrunch, October 2026], but the commercial shell is still small, with just under 10 customers and seven employees by October 2026, according to TechCrunch [TechCrunch, October 2026].
The exposure is straightforward: Intero has not yet shown a public channel advantage, a named enterprise customer base, or a broad platform footprint outside the intestine. That leaves it vulnerable to any better-capitalized organoid or preclinical-tools company that can offer multi-organ coverage, deeper validation data, or easier procurement through existing pharma vendor relationships. Public sources do not identify a named rival with those attributes, so the sharper comparison is category-level: animal studies keep the advantage of regulatory familiarity, while simpler in vitro assays keep the advantage of lower cost and easier integration into established screening workflows [Forbes, December 2025] [Trend Hunter]. Intero's challenge is that being more biologically realistic does not, by itself, guarantee budget line ownership.
The most plausible 18-month scenario is a split market rather than a winner-take-all outcome. Intero could be a winner if intestinal safety screening becomes a standard add-on for pharma programs that already suspect GI liability, especially if the company converts its reported early customer base into repeat studies and publishes clearer validation benchmarks against incumbent methods [TechCrunch, October 2026] [SBIR.gov]. The likely loser if that validation does not arrive is the broader category of animal-first intestinal screening in the specific niches where organoids can show better human relevance [Forbes, December 2025]. The reverse scenario is also credible: incumbent animal and low-complexity assay workflows remain the practical winner if buyers decide Intero's added biological complexity does not yet justify changes to procurement, validation, and study design.
Opportunity
PUBLIC
The prize here is not a niche assay business, but a shot at becoming a standard preclinical testing layer for compounds that carry meaningful gastrointestinal safety or efficacy questions, if Intero can turn an academic organoid advance into repeatable commercial workflows for drugmakers [TechCrunch, October 2026] [Intero Biosystems, Unknown].
The headline opportunity is fairly specific. Intero is building human intestinal organoids for preclinical testing, and its core claim is that GastroScreen offers a more human-relevant model than animal studies or simpler cell systems for certain gut-related questions [TechCrunch, October 2026] [Intero Biosystems, Unknown]. That outcome is still early, but it is not purely conceptual: the company had raised a reported $2.3 million pre-seed round by October 2026, had just under 10 customers, and had seven employees, while studies were underway with several pharmaceutical companies according to TechCrunch [TechCrunch, October 2026]. For a company founded in 2024, that combination matters because it suggests the product is already being bought and evaluated in real screening workflows, not only discussed in grant or competition settings [TechCrunch, October 2026] [Intero Biosystems, June 2025].
A plausible upside case is that Intero becomes less a seller of organoids and more a decision-support layer inside preclinical development. The product is described as a human intestinal-organoid model for pharmaceutical, biotechnology, food, and chemical companies, and public materials frame it as useful for assessing cytotoxicity, off-target effects, and epithelial barrier disruption before human trials [TechCrunch, October 2026] [Intero Biosystems, Unknown]. If those use cases continue to validate, the company could expand from single-study purchases into recurring screening programs, longitudinal tox libraries, and eventually a position in go or no-go decisions for compounds where gut biology is a gating risk. That is the path from interesting platform to durable budget line.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Pharma wedge to standard workflow | Intero starts with intestinal safety studies, then becomes a repeat vendor across multiple preclinical programs at the same drugmaker | A named large-pharma project converts into repeat work across existing compounds and new candidates | TechCrunch reported studies underway with several pharmaceutical companies, and Santa Clara University Bronco Ventures said the company had secured its first pharmaceutical customer and begun a major project with a large pharma partner [TechCrunch, October 2026] [Santa Clara University Bronco Ventures, October 2026] |
| Category leader in human-relevant GI testing | GastroScreen becomes a recognized default model for gut-specific preclinical questions across pharma, biotech, food, and chemicals | Independent proof that the organoids consistently surface toxicity or efficacy signals missed by animal or flat-cell models | The company positions GastroScreen across four buyer groups, and public descriptions consistently emphasize human-relevant biology and reduced reliance on animal models [TechCrunch, October 2026] [Forbes, December 2025] [Intero Biosystems, Unknown] |
| Platform expansion from one organ system | The intestinal model becomes the first commercial entry point into a broader organoid-testing platform and data asset | Successful manufacturing scale-up and repeatable assay validation make adjacent products fundable and sellable | The website describes "miniature organs for preclinical testing," not a single bespoke research service, and the company has advertised for a principal scientist in manufacturing, which is consistent with productization rather than one-off academic output [Intero Biosystems, Unknown] [LinkedIn] |
The compounding dynamic is straightforward if the early customer work holds up. Each additional pharma study can generate more comparative data on how compounds behave in Intero's intestinal model, which in turn can make assay design, benchmark ranges, and interpretation more credible for the next customer [TechCrunch, October 2026] [Intero Biosystems, Unknown]. In a business like this, trust accumulates through repeated use cases rather than consumer-style network effects. A first pharmaceutical customer, a reported major pharma project, and fewer than 10 customers at this stage suggest the flywheel is only beginning, but it is visible: more studies can mean more validation, more validation can mean a lower sales burden, and a lower sales burden can support broader deployment inside the same accounts [Santa Clara University Bronco Ventures, October 2026] [TechCrunch, October 2026].
The size of the win is hard to anchor precisely from the public record because no external market-sizing source is provided in the source set. Even so, there is a reasonable scenario frame. If Intero became a category-leading provider of human-relevant intestinal preclinical testing and converted early assay revenue into a broader platform position with large drugmakers, the outcome could support a venture-scale business rather than a tools niche. A practical public marker is not a direct valuation comparable, but the fact pattern of early commercialization: a 2024-founded company with reported customers, pharma studies underway, and competition wins that brought non-dilutive visibility and funding into the business [TechCrunch, October 2026] [Intero Biosystems, June 2025]. In that scenario, not a forecast, the company could plausibly grow into an acquisition target for a larger life sciences tools or drug-development platform, or into an independent venture-backed testing company valued on strategic importance to preclinical R&D rather than on simple reagent sales alone [Forbes, December 2025] [TechCrunch, October 2026].
One source, partially checked -- This section relies primarily on TechCrunch and company materials, with partial corroboration from Santa Clara University Bronco Ventures and Forbes.
Sources
Publicly reported
[Intero Biosystems, June 2025] Press Release - June 11th, 2025 | Intero Biosystems | https://www.interobiosystems.com/press-release-june-11th-2025/
[TechCrunch, October 2026] Intero Biosystems wants drugmakers to test on mini human intestines, not animals | TechCrunch | https://techcrunch.com/2026/10/14/intero-biosystems-wants-drugmakers-to-test-on-mini-human-intestines-not-animals/
[Center for Entrepreneurship] Fuel: Intero Biosystems Ignites Innovation as September Winner | Center for Entrepreneurship | https://cfe.umich.edu/fuel-interobiosystems-ignites-innovation-as-september-winner/
[The Diligent Observer, August 2025] Bargain Hunting in the Series B Aisle, Lab-Grown Guts, and Fresh Intel from Nearly 70 Angel Groups | The Diligent Observer | https://www.thediligentobserver.com/p/angeldealsoftheweek-8-28-25
[SBIR.gov] Human Intestinal Organoid Model for Drug Toxicity Screening | SBIR.gov | https://www.sbir.gov/
[Tech Bytes, 2026] And the winner of Startup Battlefield at Disrupt 2026 is: Intero Biosystems | Tech Bytes | https://techbytes.app/posts/and-the-winner-of-startup-battlefield-at-disrupt-2026-is/
[Crunchbase] Intero Biosystems - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/intero-biosystems
[Forbes, December 2025] 30 Under 30 Healthcare 2026: Using AI To Improve Care And Cut Administrative Burdens | Forbes | https://www.forbes.com/sites/alexknapp/2025/12/02/30-under-30-healthcare-2026-using-ai-to-improve-care-and-cut-administrative-burdens/
[Santa Clara University Bronco Ventures, October 2026] Accelerator Alumni Success Stories | https://www.scu.edu/cioccacenter/bronco-ventures/success/
[Intero Biosystems] Intero Biosystems | Miniature Organs for Preclinical Testing | https://www.interobiosystems.com/
[LinkedIn] Intero Biosystems | LinkedIn | https://www.linkedin.com/company/intero-biosystems
[The Spence Lab @ the university of michigan, April 2025] Intero Wins Grand Prize at Rice Business Plan Competition | https://medicine.umich.edu/dept/cdb/spence-lab
[BIO International Convention 2025] BIO 2025 Exhibitor or Program Listing for Intero Biosystems | https://www.bio.org/events/bio-international-convention
[Trend Hunter] GastroScreen | Trend Hunter | https://www.trendhunter.com/
[Межа] Intero Biosystems coverage | https://mezha.media/
[LinkedIn] Jason R. Spence - University of Michigan | LinkedIn | https://www.linkedin.com/in/jason-r-spence-62825462/
[Biomedical Engineering (BME), April 2025] Intero Biosystems wins Rice Business Plan Competition | Biomedical Engineering | https://bme.umich.edu/
[TechCrunch, October 2026] And the winner of Startup Battlefield at Disrupt 2026 is: Intero Biosystems | TechCrunch | https://techcrunch.com/2026/10/15/and-the-winner-of-startup-battlefield-at-disrupt-2026-is-intero-biosystems/
Articles about Intero Biosystems
- Intero Biosystems Wins TechCrunch Battlefield With a Millimeter of Human Gut — The Denver-based spinout, which just won Startup Battlefield 2026, is selling its lab-grown GastroScreen organoids to pharma and biotech companies for preclinical testing.